340B Drug Pricing Program
President Trump today unveiled his administration’s blueprint to lower prescription drug prices, which also solicits input on potential actions the Department of Health and Human Services may take to improve competition and negotiation and lower costs.
Contact: Marie Johnson, (202) 626-2351
Colin Milligan, (202) 638-5491
Watch the video
The timing of the AHA Annual Membership Meeting presents a “real opportunity to talk with your members of Congress about what you are doing back home,” specifically how hospitals are improving value and affordability, coping with escalating drug prices and working at the front…
Oral arguments today in a federal appeals court case brought by the AHA, Association of American Medical Colleges, America’s Essential Hospitals and three hospital organizations to challenge a nearly 30% reduction to Medicare payments for 340B drugs focused on procedure issues.
The Department of Health and Human Services today proposed delaying to July 1, 2019 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers.
Rep. Earl “Buddy” Carter (R-GA) yesterday introduced a bill that would require hospitals participating in the 340B drug savings program to report their low-income utilization rate for outpatient services.
Key Resources
AHA Special Bulletin: AHA Files Motions in 340B Case
AHA 340B Factsheet
Fact Sheet: 340B Drug Pricing Program Contract Pharmacy Arrangements
A number of studies – many paid for and supported by the pharmaceutical industry – have come out in recent years examining the 340B drug savings program. The AHA has responded to a number of these studies attempting to set the record straight on the 340B program.
The AHA, Association of American Medical Colleges, America’s Essential Hospitals, Eastern Maine Healthcare Systems, Henry Ford Health System and Adventist Health System's Park Ridge Health yesterday urged a federal appeals court to find that they are entitled a preliminary injunction in their…